HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 18, Issue 3, Pages 495-512 (July 2008)


View previous. 11 of 20 View next.

Barrett's Esophagus: Pathogenesis, Treatment, and Prevention

Rami J. Badreddine, MD, Kenneth K. Wang, MDCorresponding Author Informationemail address

Esophageal adenocarcinoma is the most common type of esophageal cancer seen in the United States and Western Europe. Barrett's esophagus (BE) is a well-known risk factor for esophageal adenocarcinoma and is believed to be found in 6% to 12% of patients undergoing endoscopy for gastroesophageal reflux disease and in more than 1% of all patients undergoing endoscopy. This article focuses on the pathogenesis, treatment, and prevention of BE.

Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA

Corresponding Author InformationCorresponding author. Barrett's Esophagus Unit, Alfred Main, Gastroenterology Diagnostic Unit, St. Mary's Hospital, 200 1st Street SW, Rochester, MN 55905.

 Supported by NIH Grants R01 CA111603-01A1, R01CA097048, and R21CA122426-01.

PII: S1052-5157(08)00042-1

doi:10.1016/j.giec.2008.05.005


View previous. 11 of 20 View next.